MarketSulfadiazine
Company Profile

Sulfadiazine

Sulfadiazine is an antibiotic. Used together with pyrimethamine, a dihydrofolate reductase inhibitor, it is the treatment of choice for toxoplasmosis, which is caused by a protozoan parasite. It is a second-line treatment for otitis media, prophylaxis of rheumatic fever, chancroid, chlamydia, and infections by Haemophilus influenzae. It is also used as adjunct therapy for chloroquine-resistant malaria and several forms of bacterial meningitis. It is taken by mouth. Sulfadiazine is available in multiple generic tablets of 500 mg. For urinary tract infections, the usual dose is 4 to 6 grams daily in 3 to 6 divided doses.

Medical uses
It eliminates bacteria that cause infections by stopping the production of folate inside the bacterial cell, and is commonly used to treat urinary tract infections and burns. In combination, sulfadiazine and pyrimethamine can be used to treat toxoplasmosis, the disease caused by Toxoplasma gondii. ==Other uses==
Other uses
Sulfadiazine is used in plant research for selecting and maintaining genetically manipulated cells. ==Mechanism of action==
Mechanism of action
Sulfadiazine works by inhibiting the enzyme dihydropteroate synthetase. ==Side effects==
Side effects
Side effects reported for sulfadiazine include nausea, loss of appetite, dizziness, gastrointestinal upset, rash and fever. == Brand names ==
Brand names
This drug is sold branded as Lantrisul, Neotrizine, Sulfadiazine, Sulfaloid, Sulfonamides Duplex and Sulfose. "Triple sulfa" (or trisulfapyrimidines) is a name often given to a combination of sulfadiazine with sulfamerazine and sulfamethazine. This is marketed under brand names such as Sulfa-Triple #2, Terfonyl, Triple Sulfa, Triple Sulfas and Triple Sulfoid. == See also ==
tickerdossier.comtickerdossier.substack.com